A new combination of drugs could help delay the advancement of a deadly form of prostate cancer in those with an advanced form of the disease, new research has found.
The “striking” findings showed an overall upward trend in life expectancy when patients took niraparib - a targeted therapy that blocks cancer cells from repairing their DNA when damaged - alongside the standard abiraterone acetate and prednisone treatments.
